83904
document
[ The anti-ischemic effect of phosphodiesterase III inhibitors ] . When enoximone is acutely administered to patients with stable angina and angiographically proven relevant coronary stenosis i.v . application of 0.75 mg/kg exhibits pronounced antiischemic effects . This could be observed in patients during exercise and in those in whom the ischemia was provoked by rapid cardiac stimulation . The antiischemic effects were documented by relief of symptoms , reduction of ST-depression , improvement of impaired myocardial wall motion , decrease to normalization of pathologically elevated filling pressure , amelioration of coronary blood flow as evidenced by myocard scintigraphy and washout time of an intracoronarily injected echo-contrast medium . There was also a definite improvement of ischemia-caused mitral regurgitation . Similar observations were found when the drug was injected in the diseased coronary arteries in a small dose ( 0.075 mg/kg ) so that peripheral effects were not present . In comparison to the Ca ( ++ ) -blocker Gallopamil the antiischemic effects of Enoximone were more pronounced , a synergistic action was , however , observed . Negative dromotropic effects of Gallopamil could be abolished by Enoximone . With oral administration of the drug over a period of one week antiischemic effects could also be documented with Holter monitoring as well as during exercise . There was a reduction of ST-depression both at spontaneously occurring ischemic episodes and during exercise , in the number and duration of episodes of silent ischemia , particularly , however , a decrease in symptomatic episodes . In none of the patients under study proarrhythmic effects were observed .
83905
Intervention_Pharmacological
enoximone
83906
Intervention_Pharmacological
Gallopamil
83907
Intervention_Pharmacological
Enoximone
83908
Intervention_Pharmacological
Gallopamil
83909
Intervention_Pharmacological
Enoximone
83910
Outcome_Physical
anti-ischemic effect
83911
Outcome_Physical
antiischemic effects
83912
Outcome_Physical
ischemia
83913
Outcome_Physical
antiischemic effects
83914
Outcome_Other
relief of symptoms
83915
Outcome_Physical
ST-depression
83916
Outcome_Physical
myocardial wall motion
83917
Outcome_Physical
pathologically elevated filling pressure
83918
Outcome_Physical
amelioration of coronary blood flow
83919
Outcome_Physical
ischemia-caused mitral regurgitation
83920
Outcome_Physical
peripheral effects
83921
Outcome_Physical
antiischemic effects
83922
Outcome_Physical
synergistic action
83923
Outcome_Physical
Negative dromotropic effects
83924
Outcome_Physical
antiischemic effects
83925
Outcome_Other
Holter monitoring
83926
Outcome_Physical
ST-depression
83927
Outcome_Physical
number and duration of episodes of silent ischemia
83928
Outcome_Physical
symptomatic episodes
83929
Outcome_Physical
proarrhythmic effects
83930
Participant_Condition
patients with stable angina and angiographically proven relevant coronary stenosis i.v . application of 0.75 mg/kg